Fertility-sparing tx feasible in early endometrial cancer

October 30, 2012
Fertility-sparing tx feasible in early endometrial cancer
For women with early-stage endometrial cancer and atypical complex hyperplasia, fertility-sparing treatment seems feasible, according to research published in the October issue of the American Journal of Obstetrics & Gynecology.

(HealthDay)—For women with early-stage endometrial cancer (EC) and atypical complex hyperplasia (ACH), fertility-sparing treatment seems feasible, according to research published in the October issue of the American Journal of Obstetrics & Gynecology.

Ioannis D. Gallos, M.D., from the Birmingham Women's Hospital in the United Kingdom, and colleagues conducted a systematic review and meta-analysis to examine the regression, relapse, and live birth rates for women with EC and ACH who underwent fertility-sparing treatment. A total of 34 observational studies, involving 408 women with EC and 151 women with ACH were included.

The researchers found that, for EC, fertility-sparing treatment achieved a pooled regression rate of 76.2 percent, a relapse rate of 40.6 percent, and a live birth rate of 28 percent. The corresponding figures for ACH were 85.6, 26, and 26.3 percent. During follow-up, 3.6 percent of women were diagnosed with ovarian (concurrent or metastatic), 1.9 percent of women (10 women) progressed to disease higher than stage I EC, and two of these 10 died.

"In conclusion, this review of observational studies found a high chance of disease regression and encouraging live birth rates of early-stage EC and ACH with fertility-sparing treatment followed by assisted reproduction," the authors write. "Our systematic examination of the published literature confirms that there is only moderate-quality observational evidence to inform clinical practice, and results should be interpreted with caution."

Explore further: Confusion about emergency contraception access common

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Confusion about emergency contraception access common

March 26, 2012
(HealthDay) -- While most pharmacies report having emergency contraception (EC) in stock, misinformation regarding what age women can take it without a prescription is common, according to a study published online March 26 ...

Fertility treatment: Safer drug for women leads to same live birth rate

May 11, 2011
With new information available, authors of a Cochrane Systematic Review have revised their conclusions about the relative effectiveness of two different treatments used to help women become pregnant. They now conclude that ...

Few young women with cancer take steps to preserve fertility during treatments

March 26, 2012
A new study has found that very few young women with cancer take steps to preserve their fertility while undergoing cancer therapy. Also, certain groups of young women are more likely to do so than others. Published early ...

ART live-birth rates can approach natural fecundity

June 28, 2012
(HealthDay) -- During assisted reproductive technology, increasing maternal age and number of cycles is linked to lower live-birth rates with the use of autologous oocytes, but not donor oocytes, according to a study published ...

‘Infertile’ women may just need longer to conceive

February 20, 2012
(Medical Xpress) -- One-in-four women with a history of infertility can still end up having a baby without treatment, a new study from The University of Queensland (UQ) shows.

Recommended for you

Soy, cruciferous vegetables associated with fewer common breast cancer treatment side effects

December 11, 2017
Consuming soy foods (such as soy milk, tofu and edamame) and cruciferous vegetables (such as cabbages, kale, collard greens, bok choy, Brussels sprouts, and broccoli) may be associated with a reduction in common side effects ...

CAR T, immunotherapy bring new hope for multiple myeloma patients

December 11, 2017
Two investigational immunotherapy approaches, including chimeric antigen receptor (CAR) T cell therapy, have shown encouraging results in the treatment of multiple myeloma patients who had relapsed and were resistant to other ...

Tracking how multiple myeloma evolves by sequencing DNA in the blood

December 10, 2017
Although people with multiple myeloma usually respond well to treatment, the blood cancer generally keeps coming back. Following genetic changes in how the disease evolves over time will help to understand the disease and, ...

Landmark CAR-T cancer study published

December 10, 2017
Loyola University Medical Center is the only Chicago center that participated in the pivotal clinical trial of a groundbreaking cancer treatment that genetically engineers a patient's immune system to attack cancer cells.

Study finds emojis promising tool for tracking cancer patients' quality of life

December 10, 2017
In findings presented to the American Society of Hematology, Mayo Clinic researchers found that using emojis instead of traditional emotional scales were helpful in assessing patients' physical, emotional and overall quality ...

Study explores use of checkpoint inhibitors after relapse from donor stem cell transplant

December 10, 2017
Immunotherapy agents known as checkpoint inhibitors have shown considerable promise in patients with hematologic cancers who relapse after a transplant with donor stem cells. Preliminary results from the first clinical trial ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.